Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

This is a trial of Ateronon in Patients with Coronary Disease to Evaluate its Effectiveness in Assessing the Risk Factors of Atherosclerosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atherosclerosis Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Vascular Diseases

Age range

35 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Rafic Hariri University Hospital

Beirut, Bir Hasan, Lebanon

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Men and Women with demonstrated Coronary Disease
AtheroAbzyme positive during screening process
Elevated Total Cholesterol
Willingness to take study nutritional supplement once a day for 3 months

Exclusion criteria

Women who are pregnant, nursing or intend pregnancy during the period of treatment
Known milk, soy or whey allergy

Treatment and study plan

Ateronon

Drug

Ateronon daily for 3 months

Primary outcomes

to evaluate the effectiveness of Ateronon in inhibiting atherogenic lipid oxidation in patients with demonstrated coronary disease

Time frame: Baseline and 3 months

Secondary outcomes

to evaluate the potential effectiveness of Ateronon in lowering pulse rate as well systolic and diastolic blood pressure in patients with demonstrated coronary disease

Time frame: Baseline and 3 months

Sponsors and collaborators

Lead sponsor

Omicron Pharmaceuticals

Industry

Registry information

Important dates

Study start: 2011
Primary completion: 2011
Study completion: 2011
First posted: Feb 1, 2011
Registry last updated: May 21, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed